Digest Network Come funziona
Network
/
Società
Co
Non verificato

Cofactor Genomics, Inc.

Di cosa scriviamo

BiotecnologiaOncologiaSaluteSanitàScienza

6 comunicati stampa

Guarda tutti i comunicati
12/02/2025
Tecnica
Scienza
Biotecnologia
Salute
Sanità
Oncologia
Analisi di mercato
Industria
Cofactor Genomics Publishes Analytical Validation of OncoPrism-HNSCC, Highlighting Robustness of The AI-powered RNA Test In Predicting Cancer Patient Response To Immunotherapy
Fonte
Cofactor Genomics, Inc.
Emittente
Business Wire
1.00
0
08/01/2025
Mercato del lavoro
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Farmaceutica
Salute
Oncologia
Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test
Fonte
Cofactor Genomics, Inc.
Emittente
Business Wire
1.00
0
15/11/2024
Scienza
Tecnica
Biotecnologia
Sanità
Salute
Oncologia
Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer Patients
Fonte
Cofactor Genomics, Inc.
Emittente
Business Wire
1.00
0
07/11/2024
Industria
Scienza
Sanità
Oncologia
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Salute
Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to Immunotherapy
Fonte
Cofactor Genomics, Inc.
Emittente
Business Wire
1.00
0
29/10/2024
Mercato del lavoro
Scienza
Sanità
Biotecnologia
Medicina - Varie
Farmaceutica
Salute
Precision Medicine Global Thought Leader, Dr. Howard McLeod, Joins Cofactor Genomics’ Advisory Board as Cofactor Brings OncoPrism test to Partnered Hospitals
Fonte
Cofactor Genomics, Inc.
Emittente
Business Wire
1.00
0
18/10/2024
Scienza
Sanità
Associazioni/Professionisti
Farmaceutica
Oncologia
Finanza
Biotecnologia
Medicina - Varie
Salute
Cofactor Genomics receives Medicare coverage for OncoPrism®, a machine learning-based RNA oncology test predicting immunotherapy response
Fonte
Cofactor Genomics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0